Over the last decade, the disease that has benefited the most from the introduction of anti-
CD20 immunotherapy has been diffuse large B-cell lymphoma (DLBCL). The most widely …

The purpose of this study was to assess the predictive and prognostic value of interim FDG
PET (iPET) in evaluating early response to immunochemotherapy after 2 cycles (PET-2) in …

We aimed to assess the interobserver agreement of interim PET (I-PET) and end-of-
treatment PET (EoT-PET) using the Deauville score (DS) in first-line diffuse large B-cell …

The International Atomic Energy Agency sponsored a large, multinational, prospective study
to further define PET for risk stratification of diffuse large B-cell lymphoma and to test the …

Interim 18F-fluorodeoxyglucose positron emission tomography performed early during the
course of therapy in diffuse large B-cell lymphoma is highly predictive of outcome and now …

PET using 18F-FDG has prognostic value when performed at the completion of initial
chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL). 18F-FDG PET may …

1603 Objectives The prognostic value of early interim fluorodeoxyglucose (18 F-FDG)
positron emission tomography/computed tomography (PET/CT) is debated in patients with …

This study investigated whether the reference background above which a residual mass is
considered positive in the International Harmonization Project criteria should be modified for …

Interim 18F-FDG PET (after 1–4 cycles of chemotherapy) may be useful for tailoring a risk-
adapted therapeutic strategy in lymphoma. The purpose of this study was to investigate …

Introduction Diffuse large B-Cell lymphoma (DLBCL) is the most common subtype of non-
Hodgkin lymphoma (NHL). Up to one third of patients relapse or fail to achieve complete …